Downloads: 82

Files in This Item:
File Description SizeFormat 
jdi.12858.pdf383.14 kBAdobe PDFView/Open
Title: Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after init
Authors: Usui, Ryota  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-4641-0158 (unconfirmed)
Sakuramachi, Yui
Seino, Yusuke
Murotani, Kenta
Kuwata, Hitoshi
Tatsuoka, Hisato  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-0669-6825 (unconfirmed)
Hamamoto, Yoshiyuki
Kurose, Takeshi
Seino, Yutaka
Yabe, Daisuke  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-5334-7687 (unconfirmed)
Author's alias: 矢部, 大介
Issue Date: Jul-2018
Publisher: Wiley
Journal title: Journal of Diabetes Investigation
Volume: 9
Issue: 4
Start page: 981
End page: 983
Abstract: We have reported that the HbA1c‐lowering effects of liraglutide/basal insulin combination rely on remaining β‐cell function and that the cut‐off value of the C‐peptide immunoreactivity index (CPI), a β‐cell function‐related index frequently used in Japanese clinical settings, is 1.103 for the achievement of HbA1c <7.0% at 54 weeks after initiating the liraglutide/basal insulin combination. Wilbrink et al claimed that glucose‐lowering effects of glucagon‐like peptide‐1 receptor agonist liraglutide depend of duration of type 2 diabetes; while our resent study published in the Journal of Diabetes Investigation failed to detect such dependency. This discrepancy might be due to several reasons including co‐administration of basal insulin with liraglutide in our study; ethnic difference in T2D pathophysiology between the two study; and difference in sample size (The Usui study on liraglutide/basal insulin, n = 38; the Usui study on liraglutide monotherapy or SU combination, n=88; and the Wilbrink study, n = 69).
Rights: © 2018 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
URI: http://hdl.handle.net/2433/236656
DOI(Published Version): 10.1111/jdi.12858
PubMed ID: 29974670
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.